Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ag10 Hydrochloride
2. Ag-10 Hydrochloride
3. Alxn2060 Hydrochloride
4. Acoramidis (hydrochloride)
5. Alxn-2060 Hydrochloride
6. Vy9c88c2nv
7. Acoramidis Hydrochloride [usan]
8. 2242751-53-5
9. Benzoic Acid, 3-(3-(3,5-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluoro-, Hydrochloride (1:1)
10. Unii-vy9c88c2nv
11. Chembl4650226
12. Schembl20475239
13. Acoramidis Hydrochloride [jan]
14. Hy-109165a
15. Cs-0143619
16. 3-(3-(3-5-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluorobenzoic Acid Hydrochloride
Molecular Weight | 328.76 g/mol |
---|---|
Molecular Formula | C15H18ClFN2O3 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 6 |
Exact Mass | 328.0989983 g/mol |
Monoisotopic Mass | 328.0989983 g/mol |
Topological Polar Surface Area | 75.2 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 356 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
NDC Package Code : 59116-5910
Start Marketing Date : 2021-12-30
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59116-5911
Start Marketing Date : 2021-12-30
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Details:
Attruby (acoramidis) is a next-generation, orally-administered, highly potent, small molecule stabiliser of transthyretin. It is approved for the treatment of Transthyretin Amyloid Cardiomyopathy.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Brand Name: Attruby
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2024
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Attruby™ Approved by FDA for Reducing Deaths in ATTR-CM Cardiovascular Patients
Details : Attruby (acoramidis) is a next-generation, orally-administered, highly potent, small molecule stabiliser of transthyretin. It is approved for the treatment of Transthyretin Amyloid Cardiomyopathy.
Brand Name : Attruby
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 22, 2024
Details:
Attruby (acoramidis) is a next-gen orally-administered, stabiliser of transthyretin (TTR). It is being indicated for the treatment of Transthyretin Amyloid Cardiomyopathy.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Brand Name: Attruby
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2024
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
US FDA Approves Bridgebio's Drug for Rare Heart Condition
Details : Attruby (acoramidis) is a next-gen orally-administered, stabiliser of transthyretin (TTR). It is being indicated for the treatment of Transthyretin Amyloid Cardiomyopathy.
Brand Name : Attruby
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 22, 2024
Details:
The net proceeds will be used in the development of AG10 (acoramidis HCl). Which is being evaluated in the Phase III clinical trial studies for the treatment of Transthyretin Amyloid Cardiomyopathy.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Brand Name: AG10
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: J.P. Morgan
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 04, 2024
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $250.0 million
Deal Type : Public Offering
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
Details : The net proceeds will be used in the development of AG10 (acoramidis HCl). Which is being evaluated in the Phase III clinical trial studies for the treatment of Transthyretin Amyloid Cardiomyopathy.
Brand Name : AG10
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 04, 2024
Details:
BridgeBio grants Bayer an exclusive license to commercialize acoramidis, a small molecule stabilizer of TTR for ATTR-CM patients in Europe.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Brand Name: AG10
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Bayer AG
Deal Size: Undisclosed Upfront Cash: $310.0 million
Deal Type: Licensing Agreement March 04, 2024
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Bayer AG
Deal Size : Undisclosed
Deal Type : Licensing Agreement
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
Details : BridgeBio grants Bayer an exclusive license to commercialize acoramidis, a small molecule stabilizer of TTR for ATTR-CM patients in Europe.
Brand Name : AG10
Molecule Type : Small molecule
Upfront Cash : $310.0 million
March 04, 2024
Details:
Bayer acquires commercialization rights for AG10 (acoramidis), an oral transthyretin stabilizer for ATTR CM in Europe.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Brand Name: AG10
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Bayer AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 04, 2024
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Bayer AG
Deal Size : Undisclosed
Deal Type : Acquisition
Bayer Strengthens Pharma Portfolio with New Cardiology Drug Acoramidis
Details : Bayer acquires commercialization rights for AG10 (acoramidis), an oral transthyretin stabilizer for ATTR CM in Europe.
Brand Name : AG10
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 04, 2024
Details:
AG-10 (acoramidis) is an investigational, orally-administered small molecule stabilizer of transthyretin (TTR), evaluated in Phase 3 trials for Transthyretin Amyloid Cardiomyopathy treatment.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Brand Name: AG10
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Alexion Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2024
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Alexion Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
BridgeBio Reports Positive Results for Acoramidis in ATTR-CM Phase 3 Study
Details : AG-10 (acoramidis) is an investigational, orally-administered small molecule stabilizer of transthyretin (TTR), evaluated in Phase 3 trials for Transthyretin Amyloid Cardiomyopathy treatment.
Brand Name : AG10
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 02, 2024
Details:
The net proceeds will be used in the anticipated launch of AG10 (acoramidis HCl) as the potential backbone of therapy for transthyretin amyloid cardiomyopathy (ATTR-CM).
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Rare Diseases and Disorders Brand Name: AG10
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Blue Owl Capital
Deal Size: $500.0 million Upfront Cash: $500.0 million
Deal Type: Financing January 18, 2024
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Blue Owl Capital
Deal Size : $500.0 million
Deal Type : Financing
BridgeBio Secures Up to $1.25 Billion from Blue Owl to Advance Genetic Drug Development
Details : The net proceeds will be used in the anticipated launch of AG10 (acoramidis HCl) as the potential backbone of therapy for transthyretin amyloid cardiomyopathy (ATTR-CM).
Brand Name : AG10
Molecule Type : Small molecule
Upfront Cash : $500.0 million
January 18, 2024
Details:
AG10 (acoramidis) is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin (TTR), being investigated for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Brand Name: AG10
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AG10 (acoramidis) is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin (TTR), being investigated for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).
Brand Name : AG10
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 05, 2023
Details:
The net proceeds will fund the launch of AG10 (acoramidis), an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin (TTR), and company's upcoming Phase 3 readouts in achondroplasia, LGMD2I, and ADH1.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: AG10
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Qatar Investment Authority
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 25, 2023
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Qatar Investment Authority
Deal Size : $250.0 million
Deal Type : Private Placement
BridgeBio Pharma Announces $250 Million Private Placement Equity Financing
Details : The net proceeds will fund the launch of AG10 (acoramidis), an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin (TTR), and company's upcoming Phase 3 readouts in achondroplasia, LGMD2I, and ADH1.
Brand Name : AG10
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 25, 2023
Details:
AG10 (acoramidis) is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin (TTR), being investigated for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Rare Diseases and Disorders Brand Name: AG10
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Alexion Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Alexion Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AG10 (acoramidis) is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin (TTR), being investigated for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).
Brand Name : AG10
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 17, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?